Management of Diabetes Mellitus in Acromegaly and Cushing’s Disease with Focus on Pasireotide Therapy: A Narrative Review

References

• Sanno N, Teramoto A, Osamura RY, et al. Pathology of pituitary tumors. Neurosurg Clin N Am. 2003;14(1):25–39. doi:10.1016/s1042-3680(02)00035-9
   PubMed Web of Science ®Google Scholar
• Tritos NA, Miller KK. Diagnosis and management of pituitary adenomas: a review. JAMA. 2023;239(16):1386–1389. doi:10.1001/jama.2023.5444
   Google Scholar
• Katznelson L, Laws ER, Helmed S, et al. Acromegaly: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933–3951. doi:10.1210/jc.2014-2700
   PubMed Web of Science ®Google Scholar
• Nieman LK, Biller BMK, Findling JW, et al. Treatment of Cushing’s syndrome: an Endocrine Society clinical practice guidelines. J Clin Endocrinol Metab. 2015;100(8):2807–2831. doi:10.1210/jc.2015-1818
   PubMed Web of Science ®Google Scholar
• Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014;99(3):791–799. doi:10.1210/jc.2013-2480
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Bronstein MD, Brue T, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, Phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(11):875–884. doi:10.1016/S2213-8587(14)70169-X
   PubMed Web of Science ®Google Scholar
• Colao A, Petersenn S, Newell-Price J, et al. A 12-month Phase 3 study of pasireotide in Cushing’s disease. N Engl J Med. 2012;366(10):914–924. doi:10.1016/S2213-8587(14)70169-X
   PubMed Web of Science ®Google Scholar
• Lacroix A, Gu F, Gallardo W, et al. Efficacy and safety of once-monthly pasireotide in Cushing’s disease: a 12 month clinical trial. Lancet Diabetes Endocrinol. 2018;6(1):17–26. doi:10.1016/S2213-8587(17)30326-1
   PubMed Web of Science ®Google Scholar
• Pivonello R, Auriemma RS, Grasso LF, et al. Complications of acromegaly, cardiovascular, respiratory and metabolic comorbidities. Pituitary. 2017;20:46–62. doi:10.1007/s11102-017-0797-7
   PubMed Web of Science ®Google Scholar
• Li D, El Kawkgi OM, Henriquez AF, Bancos I. Cardiovascular risk and mortality in patients with active and treated hypercortisolism. Gland Surg. 2020;9(1):43–58. doi:10.21037/gs.2019.11.03
   PubMed Web of Science ®Google Scholar
• Ershadinia N, Tritos NA. Diagnosis and treatment of acromegaly: an update. Mayo Clin Proc. 2022;97:333–346. doi:10.1016/j.mayocp.2021.11.007
   PubMed Web of Science ®Google Scholar
• Ferraù F, Albani A, Ciresi A, Giordano C, Cannavò S. Diabetes secondary to acromegaly, physiopathology, clinical features and effects of treatment. Front Endocrinol. 2018;9:358. doi:10.3389/fendo.2018.00358
   PubMed Web of Science ®Google Scholar
• Dal J, List EO, Jørgensen JOL, Berryman DE. Glucose and fat metabolism in acromegaly: from mice models to patient care. Neuroendocrinology. 2015;103:96–105. doi:10.1159/000430819
   PubMed Web of Science ®Google Scholar
• Del Rincon JP, Iida K, Gaylinn BD, et al. Growth hormone regulation of p85α expression and phosphoinositide 3-kinase activity in adipose tissue. Diabetes. 2007;56:1638–1646. doi:10.2337/db06-0299
   PubMed Web of Science ®Google Scholar
• Moustaki M, Paschou SA, Xekouki P, et al. Secondary diabetes mellitus in acromegaly. Endocrine. 2023;81(1):1–15. doi:10.1007/s12020-023-03339-1
   PubMed Web of Science ®Google Scholar
• Kasayama S, Otsuki M, Takagi M, et al. Impaired β-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol. 2000;52:549–555. doi:10.1046/j.1365-2265.2000.00986.x
   PubMed Web of Science ®Google Scholar
• Kinoshita Y, Fujii H, Takeshita A, et al. Impaired glucose metabolism in Japanese patients with acromegaly is restored after successful pituitary surgery if pancreatic β-cell function is preserved. Eur J Endocrinol. 2011;164:467–473. doi:10.1530/EJE-10-1096
   PubMed Web of Science ®Google Scholar
• Frara S, Maffezzoni F, Mazziotti G, Giustina A. Current and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol Metab. 2016;27:470–483. doi:10.1016/j.tem.2016.04.014
   PubMed Web of Science ®Google Scholar
• Popovicu MS, Paduraru L, Nutas RM, et al. Diabetes mellitus secondary to endocrine diseases: an update of diagnostic and treatment particularities. Int J Mol Sci. 2023;24(16):12676. doi:10.3390/ijms241612676
   PubMed Web of Science ®Google Scholar
• Scaroni C, Zilio M, Foti M, Boscaro M. Glucose metabolism abnormalities in Cushing syndrome: from molecular basis to clinical management. Endocr Rev. 2017;38(3):189–219. doi:10.1210/er.2016-1105
   PubMed Web of Science ®Google Scholar
• Barbot M, Ceccato F, Scaroni C. Diabetes mellitus secondary to Cushing’s disease. Front Endocrinol. 2018;5(9):284. doi:10.3389/fendo.2018.00284
   Google Scholar
• Pivonello R, De Leo M, Vitale P, et al. Pathophysiology of diabetes mellitus in Cushing’s syndrome. Neuroendocrinology. 2010;92(Suppl 1):77–81. doi:10.1159/000314319
   PubMedGoogle Scholar
• Brennan-Speranza TC, Henneicke H, Gasparini SJ, et al. Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism. J Clin Investig. 2012;122:4172–4189. doi:10.1172/JCI63377
   PubMed Web of Science ®Google Scholar
• Eriksen M, Jensen DH, Tribler S, Holst JJ, Madsbad S, Krarup T. Reduction of insulinotropic properties of GLP-1 and GIP after glucocorticoid-induced insulin resistance. Diabetologia. 2015;58(5):920–928. doi:10.1007/s00125-015-3522-y
   PubMed Web of Science ®Google Scholar
• Jensen DH, Aaboe K, Herniksen JE, et al. Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes mellitus. Diabetologia. 2012;55(5):1406–1416. doi:10.1007/s00125-012-2459-7
   PubMed Web of Science ®Google Scholar
• Vergès B. Effects of anti-somatostatin agents on glucose metabolism. Diabetes Metab. 2017;43(5):411–415. doi:10.1016/j.diabet.2017.05.003
   PubMed Web of Science ®Google Scholar
• Silvertstein JM. Hyperglycemia induced by Pasireotide in patients with Cushing’s disease or acromegaly. Pituitary. 2016;19:536–543. doi:10.1007/s11102-016-0734-1
   PubMed Web of Science ®Google Scholar
• Puglisi S, Ferraù F, Ragonese M, Spagnolo F, Cannavò S. Cardiometabolic risk in acromegaly: a review with a focus on pasireotide. Front Endocrinol. 2020;11:28. doi:10.3389/fendo.2020.00028
   PubMed Web of Science ®Google Scholar
• Coulden A, Hamblin R, Wass J, Karavitaki N. Cardiovascular health and mortality in Cushing’s disease. Pituitary. 2022;25(5):750–753. doi:10.1007/s11102-022-01258-4
   PubMed Web of Science ®Google Scholar
• Puglisi S, Terzolo M. Hypertension and acromegaly. Endocrinol Metab Clin North Am. 2019;48:779–793. doi:10.1016/j.ecl.2019.08.008
   PubMed Web of Science ®Google Scholar
• Petrossians P, Daly AF, Natchev E, et al. Acromegaly at diagnosis in 3173 patients from the Liege Acromegaly Survey (LAS) Database. Endocr Relat Cancer. 2017;24(10):505–518. doi:10.1530/ERC-17-0253
   PubMed Web of Science ®Google Scholar
• Sharma AN, Tan M, Amsterdam EA, Singh GD. Acromegalic cardiomyopathy: epidemiology, diagnosis and management. Clin Cardiol. 2018;41(3):419–425.
   PubMed Web of Science ®Google Scholar
• Colao A, Marzullo P, Di Somma C, Lombardi G. Growth hormone and the heart. Clin Endocrinol. 2001;54(2):137–154. doi:10.1046/j.1365-2265.2001.01218.x
   PubMed Web of Science ®Google Scholar
• Marstrand P, Han L, Day SM, et al. Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: insights from the SHaRe Registry. Circulation. 2020;141(17):1371–1383. doi:10.1161/CIRCULATIONAHA.119.044366
   PubMed Web of Science ®Google Scholar
• Davì MV, Giustina A. Sleep apnea in acromegaly, a review on prevalence, pathogenetic aspects and treatment. Expert Rev Endocrinol Metab. 2012;7:55–62. doi:10.1586/eem.11.82
   PubMedGoogle Scholar
• Ragnarsson O, Olsson DS, Papakokkinou E, et al. Overall and disease-specific mortality in patients with Cushing disease: a Swedish nationwide study. J Clin Endocrinol Metab. 2019;104(6):2375–2384. doi:10.1210/jc.2018-02524
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Spiezia S, et al. Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful care. J Clin Endocrinol Metab. 1999;84(8):2664–2672. doi:10.1210/jcem.84.8.5896
   PubMed Web of Science ®Google Scholar
• Varlamov EV, Langlois F, Vila G, Fleseriu M. Management of endocrine disease: cardiovascular risk assessment, thromboembolism, and infection prevention in Cushing’s syndrome: a practical approach. Eur J Endocrinol. 2021;184(5):R207–R224. doi:10.1530/EJE-20-1309
   PubMed Web of Science ®Google Scholar
• Fallo F, Di Dalmazi G, Beuschlein F, et al. Diagnosis and management of hypertension in patients with Cushing’s syndrome: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens. 2022;40(11):2085–2101. doi:10.1097/HJH.0000000000003252
   PubMed Web of Science ®Google Scholar
• Giordano R, Picu A, Marinazzo E, et al. Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission. Clin Endocrinol. 2011;75(3):354–360. doi:10.1111/j.1365-2265.2011.04055.x
   PubMed Web of Science ®Google Scholar
• Faggiano A, Pivonello R, Spiezia S, et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing’s disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab. 2003;88(6):2527–2533. doi:10.1210/jc.2002-021558
   PubMed Web of Science ®Google Scholar
• Toja PM, Branzi G, Ciambellotti F, et al. Clinical relevance of cardiac structure and function abnormalities in patients with Cushing’s syndrome before and after cure. Clin Endocrinol. 2012;76(3):332–338. doi:10.1111/j.1365-2265.2011.04206.x
   PubMed Web of Science ®Google Scholar
• Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146(5):707–716. doi:10.1530/eje.0.1460707
   PubMed Web of Science ®Google Scholar
• Moloney KJ, Mercado JU, Ludlam WH, Mayberg MR. Pasireotide (SOM230): a novel pituitary-targeted medical therapy for the treatment of patients with Cushing’s disease. Expert Rev Endocrinol Metab. 2012;7(5):491–502. doi:10.1586/eem.12.49
   PubMedGoogle Scholar
• Singh V, Brendel MD, Zacharias S, et al. Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab. 2007;92:673–680. doi:10.1210/jc.2006-1578
   PubMed Web of Science ®Google Scholar
• Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S. Hyperglycaemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013;98:3446–3453. doi:10.1210/jc.2013-1771
   PubMed Web of Science ®Google Scholar
• Barbot M, Mondin A, Regazzo D, et al. Incretin response to mixed meal challenge in active Cushing’s disease and after pasireotide therapy. Int J Mol Sci. 2022;23:5217. doi:10.3390/ijms23095217
   PubMed Web of Science ®Google Scholar
• Schmid AH, Brueggen J. Effects of somatostatin analogs on glucose homeostasis in rats. J Endocrinol. 2012;212:49–60. doi:10.1530/JOE-11-0224
   PubMed Web of Science ®Google Scholar
• MacKenzie Feder J, Bourdeau I, Vallette S, Beauregard H, Marie LG S, Lacroix A. Pasireotide monotherapy in Cushing’s disease: a single-centre experience with 5-year extension of phase III trial. Pituitary. 2014;17(6):519–529. doi:10.1007/s11102-013-0539-4
   PubMed Web of Science ®Google Scholar
• Golor G, Hu K, Ruffin M, et al. A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers. Drug Des Devel Ther. 2012;6:71–79. doi:10.2147/DDDT.S29125
   PubMed Web of Science ®Google Scholar
• Feelders RA, Pulgar SJ, Kempel A, Pereira AM. The burden of Cushing’s disease: clinical and health-related quality of life aspects. Eur J Endocrinol. 2012;167(3):311–326. doi:10.1530/EJE-11-1095
   PubMed Web of Science ®Google Scholar
• Shen G, Darstein C, Hermosillo Resendiz K, Hu K. Pharmacokinetic and pharmacodynamic analyses of pasireotide LAR and octreotide LAR: randomized, double-blind, phase III study in patients with medically naïve acromegaly. Poster presented at: European congress of endocrinology; May 3–7; 2014; Wroclaw, Poland.
   Google Scholar
• Shen G, Darstein C, Hermosillo Resendiz K, Hu K. Analysis of pharmacokinetic (PK) and pharmacodynamic (PD) data for efficacy and safety from a randomized phase III study of pasireotide LAR in patients with acromegaly inadequately controlled on first-generation somatostatin analogs (SSA). Poster presented at: Endocrine society annual meeting; March 5–8; 2015; San Diego, CA.
   Google Scholar
• Gadelha MR, Gu F, Bronstein MD, et al. Risk factors and management of pasireotide-associated hyperglycemia in acromegaly. Endocr Connect. 2020;9(12):1178–1190. doi:10.1530/EC-20-0361
   PubMed Web of Science ®Google Scholar
• Sheppard M, Bronstein MD, Freda P, et al. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double- blind, multicenter, phase III study. Pituitary. 2015;18(3):385–394. doi:10.1007/s11102-014-0585-6
   PubMed Web of Science ®Google Scholar
• Boscaro M, Bertherat J, Findling J, et al. Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study. Pituitary. 2014;17(4):320–326. doi:10.1007/s11102-013-0503-3
   PubMed Web of Science ®Google Scholar
• Higham CE, Atkinson AB, Aylwin S, et al. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. J Clin Endocrinol Metab. 2012;97:1187–1193. doi:10.1210/jc.2011-2603
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358:1754–1759. doi:10.1016/s0140-6736(01)06844-1
   PubMed Web of Science ®Google Scholar
• Schreiber I, Buchfelder M, Droste M, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol. 2007;156:75–82. doi:10.1530/eje.1.02312
   PubMed Web of Science ®Google Scholar
• Castinetti F, Guignat L, Giraud P, et al. Ketoconazole in Cushing’s disease: is it worth a try? J Clin Endocrinol Metab. 2014;99(5):1623–1630. doi:10.1210/jc.2013-3628
   PubMed Web of Science ®Google Scholar
• Valassi E, Crespo I, Gich I, Rodrìguez J, Webb SM. A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing’s syndrome. Clin Endocrinol. 2012;77:735–742. doi:10.1111/j.1365-2265.2012.04424.x
   PubMed Web of Science ®Google Scholar
• Gadelha M, Bex M, Feelders RA, et al. Randomized trial of osilodrostat for the treatment of Cushing’s disease. J Clin Endocrinol Metab. 2022;107(7):e2882–e2895. doi:10.1210/clinem/dgac178
   PubMed Web of Science ®Google Scholar
• Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–2786. doi:10.2337/dci22-0034
   PubMed Web of Science ®Google Scholar
• Tsapas A, Avgerinos I, Karagiannis T, et al. Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. Ann Intern Med. 2020;173:278–286. doi:10.7326/M20-0864
   PubMed Web of Science ®Google Scholar
• Tsapas A, Karagiannis T, Kakotrichi P, et al. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Obes Metab. 2021;23:2116–2124. doi:10.1111/dom.14451
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al.; for the LEADER Steering Committe on behalf of the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322. doi:10.1056/NEJMoa1603827
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al.; for the REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121–130. doi:10.1016/S0140-6736(19)31149-3
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain CS, Consoli A, et al.; for the SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Eng J Med. 2016;375:1834–1844. doi:10.1056/NEJMoa1607141
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al.; for the EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;375:2117–2128. doi:10.1056/NEJMoa1504720
   Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al.; for the CANVAS Program Collaborative group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657. doi:10.1056/NEJMc1712572
   PubMed Web of Science ®Google Scholar
• The EMPA-KIDNEY Collaborative group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117–127. doi:10.1056/NEJMoa2204233
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al.; for the DAPA-CKD Trial committees and investigators.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–1446. doi:10.1056/NEJMoa2024816
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al.; for the CREDENCE Trial investigators. Canagliflozin and renal outcome in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–2306. doi:10.1056/NEJMoa1811744
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al.; for the EMPEROR-Reduced Trial investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413–1424. doi:10.1056/NEJMoa2022190
   PubMed Web of Science ®Google Scholar
• McCurray JJV, Solomon SD, Inzucchi SE, et al.; for the DAPA-HF Trial committees and investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–2008. doi:10.1056/NEJMoa1911303
   PubMed Web of Science ®Google Scholar
• Anker SD, Butler J, Filippatos G, et al.; fort the EMPEROR-Preserved Trial investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451–1461. doi:10.1056/NEJMoa2107038
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJV, Clagget B, et al.; for the DELIVER Trial committees and investigators. Dapagliflozin in heart failure with mildly reduced of preserved ejection fraction. N Engl J Med. 2022;387:1089–1098. doi:10.1056/NEJMoa2206286
   PubMed Web of Science ®Google Scholar
• Fleseriu M, Rusch E, Geer EB; on behalf of the ACCESS Study Investigators. Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study. Endocrine. 2017;55:247–255. doi:10.1007/s12020-016-1182-4
   PubMed Web of Science ®Google Scholar
• Lasolle H, Ferriere A, Vasilijevic A, Eimer S, Nunes ML, Tabarin A. Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study. Endocr Connect. 2019;8:1383–1394. doi:10.1530/EC-19-0332
   PubMed Web of Science ®Google Scholar
• Witek P, Bolanowski M, Szamotulska K, Wojciechowska-Luzniak A, Jawiarczyk-Przybylowska A, Kaluzny M. The effect of 6 month’s treatment with pasireotide LAR on glucose metabolism in patients with resistant acromegaly in Real-World clinical settings. Front Endocrinol. 2021;10(12):633944. doi:10.3389/fendo.2021.633944
   Google Scholar
• Wolf P, Dormoy A, Maione L, et al. Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR. Endocr Connect. 2022;11:e220296. doi:10.1530/EC-22-0296
   PubMed Web of Science ®Google Scholar
• Fleseriu M, Petersenn S, Biller BMK, et al. Long-term efficacy and safety of once-monthly pasireotide in Cushing’s disease: a phase III extension study. Clin Endocrinol. 2019;91:776–785. doi:10.1111/cen.14081
   PubMed Web of Science ®Google Scholar
• Pivonello R, Arnaldi G, Scaroni C, et al. The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world experience”. Endocrine. 2019;64:657–672. doi:10.3389/fendo.2020.00648
   PubMed Web of Science ®Google Scholar
• Simeoli C, Ferrigno R, De Martino MC, et al. The treatment with pasireotide in Cushing’s disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center. J Endocrinol Invest. 2020;43:57–73. doi:10.1007/s12020-015-0557-2
   PubMed Web of Science ®Google Scholar
• Sahin S, Karimova G, Özcan SG, Durcan E, Özkaya HM, Kadıoğlu P. Pasireotide treatment in Cushing’s Disease: a single tertiary center’s experience. Turk J Med Sci. 2022;52:467–476. doi:10.55730/1300-0144.5335
   PubMed Web of Science ®Google Scholar
• Samson SL, Gu F, Feldt-Rasmussen U, et al. Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study. Pituitary. 2021;24:887–903. doi:10.1007/s11102-021-01161-4
   PubMed Web of Science ®Google Scholar
• ElSayed NA, Aleppo G, Aroda VR, et al. Classification and diagnosis of diabetes: standard of Care in Diabetes- 2023. Diabetes Care. 2023;46(Suppl.1):S19–S40. doi:10.2337/dc23-S002
   PubMedGoogle Scholar
• Samson SL. Management of hyperglycemia in patients with acromegaly treated with pasireotide LAR. Drugs. 2016;76(13):1235–1243. doi:10.1007/s40265-016-0615-y
   PubMed Web of Science ®Google Scholar
• Colao A, De Block C, Gaztambide MS, Kumar S, Seufert J, Casanueva FF. Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations. Pituitary. 2014;17:180–186. doi:10.1007/s11102-013-0483-3
   PubMed Web of Science ®Google Scholar
• Breitschaft A, Hu K, Hermosillo Resendiz K, Darstein C, Golor G. Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabet Res Clin Pract. 2014;103:458–465. doi:10.1016/j.diabres.2013.12.011
   PubMed Web of Science ®Google Scholar
• Störmann S, Meyhöfer SM, Groener JB, et al. Management of pasireotide-induced hyperglycemia in patients with acromegaly: an experts’ consensus statement. Front Endocrinol. 2024;15:1348990. doi:10.3389/fendo.2024.1348990
   PubMed Web of Science ®Google Scholar
• Peracchi M, Porretti S, Gebbia C, et al. Increased glucose-dependent insulinotropic polypeptide (GIP) secretion in acromegaly. Eur J Endocrinol. 2001;145:R1–R4. doi:10.1530/eje.0.145r001
   PubMed Web of Science ®Google Scholar
• Shekhawat VS, Bhansali S, Dutta P, et al. Glucose-dependent insulinotropic polypeptide (GIP) resistance and β-cell dysfunction contribute to hyperglycaemia in acromegaly. Sci Rep. 2019;9:5646. doi:10.1038/s41598-019-41887-7
   PubMed Web of Science ®Google Scholar
• Oba-Yamamoto C, Kameda H, Miyoshi H, et al. Acromegaly cases exhibiting increased Growth Hormone levels during oral glucose loading with preadministration of dipeptidyl peptidase-4 inhibitor. Intern Med. 2021;60(15):2375–2383. doi:10.2169/internalmedicine.4755-20
   PubMed Web of Science ®Google Scholar
• Quarella M, Walser D, Brandle M, Fournier JY, Bilz S. Rapid onset of diabetic ketoacidosis after SGLT2 inhibition in a patient with unrecognized acromegaly. J Clin Endocrinol Metab. 2017;102(5):1451–1453. doi:10.1210/jc.2017-00082
   PubMed Web of Science ®Google Scholar
• Yoshida N, Goto H, Suzuki H, et al. Ketoacidosis as the initial clinical condition in nine patients with acromegaly: a review of 860 cases at a single institute. Eur J Endocrinol. 2013;169(1):127–132. doi:10.1530/eje-13-0060
   PubMed Web of Science ®Google Scholar
• Prencipe N, Bioletto F, Bona C, Gatti F, Grottoli S. Diabetic ketoacidosis in acromegaly: a case study-somatostatin analogs adverse event or disease complication? Acta Diabetol. 2020;57(4):491–493. doi:10.1007/s00592-019-01437-z
   PubMed Web of Science ®Google Scholar
• Zaina A, Grober Y, Abid A, Arad E, Golden E, Badarny S. Sodium glucose cotransporter 2 inhibitors treatment in acromegalic patients with diabetes-a case series and literature review. Endocrine. 2021;73(1):65–70. doi:10.1007/s12020-021-02718-w
   PubMed Web of Science ®Google Scholar
• Mehlich A, Bolanowski M, Mehlich D, Witek P. Medical treatment of Cushing’s disease with concurrent diabetes mellitus. Front Endocrinol. 2023;14:1174119. doi:10.3389/fendo.2023.1174119
   PubMedGoogle Scholar
• Wharton S, Davies M, Dicker D, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med. 2022;134(1):14–19. doi:10.1080/00325481.2021.2002616
   PubMed Web of Science ®Google Scholar
• He L, Wang J, Ping F, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist use with risk of gallbladder and biliary disease: a systematic review and meta-analysis of Randomized Clinical Trials. JAMA. 2022;182(5):513.519. doi:10.1001/jamainternmed.2022.0338
   Google Scholar
• Monami M, Nreu B, Scatena A, et al. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from Randomized Controlled Trials. Diabetes Obes Metab. 2017;19(9):1233–1241. doi:10.1111/dom.12926
   PubMed Web of Science ®Google Scholar
• Zaina A, Prencipe N, Golden E, et al. How to position sodium-glucose co-transporter 2 inhibitors in the management of diabetes in acromegaly patients. Endocrine. 2023;80(3):491–499. doi:10.1007/s12020-023-03352-4
   PubMed Web of Science ®Google Scholar
• Peteres AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic Diabetic Ketoacidosis: a potential complication of treatment with Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015;38(9):1687–1693. doi:10.2337/dc15-0843
   PubMed Web of Science ®Google Scholar
• Sampani E, Sarafidis P, Papagianni A. Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment. Expert Opin Drug Saf. 2020;19(6):673–682. doi:10.1080/14740338.2020.1764532
   PubMed Web of Science ®Google Scholar
• Ata F, Yousaf Z, Khan AA, et al. SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in multicentric cohort. Sci Rep. 2021;11:10293. doi:10.1038/s41598-021-89752-w
   PubMed Web of Science ®Google Scholar
• Stougaard EB, Kristensen PL, Kielgast U, et al. Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis. Diab Vasc Dis Res. 2022;19:14791641221130043.
   Web of Science ®Google Scholar
• Anson M, Zhao SS, Austin P, Ibarburu GH, Malik RA, Alam U. SGLT2i and GLP-1 RA therapy in type 1 diabetes and Reno-vascular outcomes: a real-world study. Diabetologia. 2023;66:1869–1881.
   PubMed Web of Science ®Google Scholar
• Adnan Z. Sodium Glucose Co-transporter Inhibitors in patients with acromegaly and diabetes. Trends Endocrinol Metab. 2019;30(2):77–79. doi:10.1016/j.tem.2018.11.007
   PubMed Web of Science ®Google Scholar
• McGovern AP, Hogg M, Shields BM, et al.; BM MASTERMIND consortium. Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Res Care. 2020;8(1):e001238. doi:10.1136/bmjdrc-2020-001238
   PubMed Web of Science ®Google Scholar
• The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559. doi:10.1056/NEJMoa0802743
   PubMed Web of Science ®Google Scholar
• Shikata M, Ashida K, Goto Y, et al. Pasireotide-induced hyperglycemia in a patient with Cushing’s disease: potential use of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist for treatment. Clin Case Rep. 2020;8(12):2613–2618. doi:10.1002/ccr3.3230
   PubMed Web of Science ®Google Scholar